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Abstract Background:Exhalednitricoxide (NOexp) is anindicatorofeosinophilic airwaysinflammation.This studyeval-
uated short-term variability of NOexp in13 healthy subjects (19–41years, eight males) and in 31patients with asthmatic
respiratory symptoms (19–21 years, all male) to obtain data for assessment of short-term changes of NOexp in clinical
situations. Methods:Mild asthma was confirmed in 10 patients (Group = asthma).Twenty-one patients with asthmatic
respiratory symptoms did not fulfill the functional criteria of asthma (Group = respiratory symptoms).The procedure to
determine NOexp followed the European Respiratory Society (ERS) guidelines; the mean expiratory flow used during
sampling was 0.09F0.12 l/s.NOexp for each subject was determined as themean of at least three successivemeasure-
ments at the baseline, followed by determinations at10min, 6 h and 24 h after the baseline. Results:Atthe baseline, the
mean (SD) value of NOexp was 6.6 (2.3) parts per billion (ppb) in the healthy controls, and significantly higher both in
patients with respiratory symptoms (14.6 (11) ppb, P= 0.0076) and in those with asthma (34.2 (43) ppb, Po0.001). Intra-
class correlation coefficient of NOexp measured at baseline and after an interval of10minwas 0.959 in healthy subjects,
0.986 in patientswithrespiratory symptoms and 0.936 in asthma patients, respectively.Short-termvariability in terms of
coefficientof variation (CoV) ofrepeatedmeasurementsofNOexp at10min,6 h and 24 hwas 5.1,10.8 and11.7% inhealthy
subjects,7.1,16.4 and 22.2% inpatientswithrespiratory symptoms and13.5,19.4 and 26.4% in asthmapatients, respectively.
Conclusions:Reproducibility of NOexp using standardized methods was good both in healthy subjects and in asthmatic
patients.However, in asthmatics the short-term variation of NOexp was over two times as high as in healthy subjects.
The level of NOexp was elevated, except in asthma, also in patients with asthmatic respiratory symptoms who did not
fulfill the functional criteria of asthma.r2002 Elsevier Science Ltd Allrights reserved
Available online athttp://www.sciencedirect.com
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Exhaled nitric oxide (NOexp) is known to be increased in
bronchial asthma originally demonstrated several years
ago (1^3). The inducible form of NO synthase enzyme
(iNOS) in epithelial cells of airways is evidently responsi-Received 26 October 2001, accepted in revised form 2 April 2002
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anssi.sovijarvi@hus.¢ble for the increased amount of NO in expired air in
asthma (4). In£ammatory cytokines, such as interleukin
1b and tumor necrosis factor a, induce the gene tran-
scription for the production of iNOS (5). This process
can be prevented by inhaled corticosteroids (6). Exhaled
NO correlates both with bronchial responsiveness to
histamine (7) andmetacholine and with sputum eosino-
phils inmild asthma (8).There is increasing evidence that
NOexp is a useful marker of airway in£ammation and
could be used for monitoring the response to anti-in-
£ammatory treatment in asthma (9).
896 RESPIRATORYMEDICINEReproducibility and repeatability of exhaled nitric
oxide measurements have been documented in healthy
control subjects (10^13), also in long-term (14), but not
yet in asthmatic patients. The knowledge of short-term
variation of NOexp in asthmatics as compared with
healthy subjects is essential when using NOexp in clinical
follow-up.
Any signi¢cant circadian rhythm in NOexp has not
been found inpatientswith asthma.Even inpatientswith
nocturnal asthma,NOexpwas elevatedboth during night
and day in the study by ten Hacken et al. (15).Georges et
al. (16) reported some circadian variation in NOexp in
nocturnal asthma.The aim of the present study was to
evaluate reproducibility and variability of NOexp over a
shortperiodup to 24h and to evaluate circadian changes
in NOexp in young male patients with mild asthma or
asthma-like respiratory symptoms and in healthy sub-
jects.
METHODS
Subjects
Thirty-one consecutive patients with asthmatic respira-
tory symptoms (aged 19^21, mean age 19.7 years) were
studied (Table 1). Patients had had dyspnea, wheezing,
cough, sputumproduction or symptoms related to exer-
cise during the previous month prior to the study.They
wererecruited to the study with a high suspicion of asth-
ma. All were conscripts in the Finnish army and had
passed the medical examination prior to military ser-
vice.They had had no history of respiratory infection at
least for 3 weeks preceding the present study and all
werenonsmokers.None of thepatients hadused inhaled
or oral steroids for at least 3 months and chromones forTABLE1. Subjectcharacteristics in di¡erentgroups
Healthy
n
Age Mean (range) 27.4(
Height Mean (SD) 175
Weight Mean (SD) 75
Bodymass index Mean(SD) 24
Atopics (% of subjects)
BHR % of subjects (PD15FEV1o1.6mg)
BHR % of subjects (PD15FEV1o0.4mg)
FVC % of pred Mean(SD) 100
FEV1% of pred Mean(SD) 95
NOexp (ppb) Mean(SD) 6.6
EIB fall in PEE % Mean(SD)
BHR:Bronchialhyperresponsiveness:PD15FEV1: provocative d
tory vital capacity;FEV1: forced expiratory volume in one second
constriction.at least1month prior to the study.They were allowed to
use only short-acting b-agonists as needed; the last dose
was taken at least 12h before the NOexp and lung func-
tion measurements. Asthma was con¢rmed in 10 pa-
tients (seeTable 1). Diagnosis of asthma was assessed by
the following criteria: increase of 15% or more in PEF or
forcedexpiratory volume in l s (FEV1) following a bronch-
odilatation, diurnal peak-to-peak PEF variation of 20% or
more and decrease of FEV1or PEF by13% or more from
the baseline following the standardized exercise test.
Twenty-one patients with asthmatic respiratory
symptoms did not ful¢ll the functional criteria of asthma
indicated above. Provocative dose of histamine inducing
a decrease of FEV1 by 15% (PD15FEV1) was more than
0.4mg in every subject in this group (Table 1) (17). This
group of patients was nominated as ‘‘respiratory symp-
toms’’group. Instead,40% of the asthma patients showed
PD15FEV1below 0.4mg and 90% below1.6mg.
Thirteen healthy subjects (aged19^41, eightmales and
¢ve females), with normal spirometry and no medical
history of atopic or respiratory symptoms, were also
studied as controls (Table 1). Also, all healthy subjects
were nonsmokers andhadbeen free of respiratory tract
infections for 3 weeks prior to the study. They did not
use anymedication.
Study design
All patients were studiedwith £ow^volume spirometry
and a skin-prick test on the ¢rst day (day1).On the next
day (day 2) an exercise challenge was performed. The
baseline determination of NOexp was obtained at 7^8
a.m. on the third studyday (day 3).NOexp determinations
were repeated at 10min, 6h and 24h after the baseline.subjects
= 13
Respiratory symptoms
n= 21
Asthma
n= 10
19^42) 19.7(19^21) 19.5 (19^20)
(9.8) 177(5.4) 179(6.6)
(16.2) 75(13.3) 74(8.8)
(5.7) 24(3.8) 23(3.3)
0 62 80
F 38 90
F 0 40
(5.6) 100(11.5) 104(10)
(7.9) 95(113.3) 93(9.6)
(2.3) 14.6(11.1 34.2(43)
4.7(3.4) 15.9 (4.2)
ose of histamine causinga15% fall in FEV1;FVC: forcedexpira-
:NOexp: exhalednitric oxide;EIB: exercise-induced broncho-
SHORT VARIABILITYOFEXHALEDNO 897The histamine challenge test was performed immedi-
ately after the last NOexp determination on the fourth
study day (day 4).
The healthy subjects were studied on two di¡erent
days. On the ¢rst day (day 1), baseline determination of
NOexp was performed at 7^8 a.m., following repeated
determination of NOexp 10min, 6 h and 24h thereafter.
The £ow^volume spirometry was performed for all
healthy subjects after the last NOexp determination.
This study was approved by the ethics committee of
the Department of Medicine at Helsinki University Hos-
pital and Central Military Hospital. Written informed
consentwas obtained from each participant.
Spirometry and skin-prick tests
FEV1, forced vital capacity (FVC), the ratio FEV1/FVC and
maximal expiratory £ow at 50% of FVC (MEF50) were
determined for each subject with a £ow^volume spi-
rometer (Medikro M904, Kuopio, Finland). Finnish refer-
ence values for spirometry were used (18). Skin test
were performed using the prick method with 12 com-
mon allergen extracts and a saline and a histamine con-
trol. The skin test result was regarded to be positive
when the diameter of awealwas at least 3mm.
Histamine challenge
The histamine challenge test for assessment of bronchial
responsiveness was performed using a previously de-
scribedmethod (17). A four-step dosageprocedure start-
ing from 0.025mgof bu¡eredhistamine diphosphatewas
used; themaximuminhaledhistamine dosewas1.6mg.To
determine the response, FEV1 was measured by using a
wedge spirometer (Vitalograph PF 2). If FEV1 decreased
from the baseline by15% or more after any dose, admin-
istration of histamine was discontinued. The PD15FEV1
was calculated from logarithmically transformed hista-
mine doses using linear interpolation.
Exercise challenge
The exercise challenge was performed in accordance
with a protocol described earlier (19). During an 8min
exercise, the running speed was adjusted by monitoring
the subjects’ heart rate to achieve 85% of the predicted
maximum heart rate. Exercise-induced bronchocon-
strictionwas evaluated as the post-exercise fall in PEF.
Measurement of exhaledNO
NOexpwasmeasuredusing a chemiluminesence analyzer
(Sievers 270B, Boulder, CO, U.S.A). Expiratory air £ow
andexhaledvolumeweremeasured, simultaneouslywith
NOexp, in real time with a pneumotachograph.The ana-lyzer was calibrated daily by using NO-free oxygen to
set the zero level and by a certi¢ed concentration of ni-
tric oxide in nitrogen of 184 parts per billion (ppb)(AGA
Edelgas, Germany). Before measurement, the subjects
were asked to rinse their mouth with sodium bicarbo-
nate to eliminate any NO eventually produced in the
mouth. For the measurements of end-expiratory NO,
subjects exhaled slowly fromTLC over a period of 15 s.
The exhalation £ow in the £ow window was between
0.08 and 0.15 l/s and themean exhalation £ow ranged be-
tween 0.09 and 0.12 l/s. The subjects exhaled against a
£ow resistance created by a resistor (Hans Rudolph,
Model#7100R, 50 cmH2O, £ow range 0^0.5 l/s). No
nose clipwas used.
The exhalation procedure was similar to that sug-
gested in the European guidelines on exhaled NO mea-
surements (20).The mean value of the last 100 samples,
acquired at 0.04-s intervals, was taken from a 3-s period
from the end-exhaled NO plateau. Results of the ana-
lyses were computed and graphically displayed on a plot
of NO, £ow and volume against time. At least three suc-
cessiverecordingsweremade.The acceptable coe⁄cient
of variation (CoV) of a singlemeasurementwas less than
0.15.Themean value of the recordings provided the ¢nal
result for an NOexp determination.
Statisticalmethods
Because NOexp was log-normally distributed, all subse-
quent analyses were carried out on log-transformed
data.The di¡erence between levels of NOexp in di¡erent
groups was analyzed with one-way ANOVA and pair-
wise comparisons were used with Bonferroni correc-
tion.
The reproducibility of NOexp determinations was as-
sessed with those measured after 10-min interval by
comparing the NOexp data obtained at the beseline. In-
tra-class correlation coe⁄cients (rI) after10min as com-
pared with baseline (21) were calculated for all
measurements and for each group.The CoVs compared
with beseline at10min, 6h and 24hwere also calculated.
Variability of exhaled nitric oxide was assessed at 6 and
24h after baseline by calculating the di¡erence of means
compared with baseline. This evaluation was made for
each group. A two-sided t-test was used to analyze the
di¡erence of variability in NOexp between groups. A P-
value ofo0.05 was considered signi¢cant.
RESULTS
Forty-four subjectswere studied for variabilityofNOexp
Asthma was con¢rmed in 10 patients. The mean (SD) of
NOexp at the baseline for all subjects was 16.7 (23.35)
ppb. In healthy subjects (n=13) the mean (SD) NOexp
baseline values was 6.6 (2.3) ppb; in with respiratory
898 RESPIRATORYMEDICINEsymptoms who did not ful¢ll the diagnostic criteria of
asthma (n=21) NOexp values were signi¢cantly higher
14.6 (11.1) ppb than in healthy subjects (P=0.0076). Asth-
ma patients (n=10) had the highest mean (SD) NOexp le-
vels, 34.2 (43) ppb and signi¢cantly higher when
compared with healthy subjects (Po0.001) or patients
with respiratory symptoms (P=0.02) (seeTable1).
The intra-class correlation coe⁄cient (r) was 0.955 for all
measurements between baseline and after10min. rI was
0.959 in healthy controls, 0.986 in the respiratory symp-
toms group and 0.936 in asthmatics.Themean di¡erence
of NOexp after 10min compared with baseline was
0.18ppb (Fig.1).The CoVof NOexp after10min compared
with the beseline values was 7% in the group of respira-
tory symptoms, 13.5% in asthmatics and 5% in healthy
subjects (Table 2).
Themean (SD) di¡erence between the baseline NOexp
values and thosemeasured after 6hwas 0.2 (5.5) ppb for
all study subjects (n=44). In the group of respiratory
symptoms, the di¡erence was 0.04 (5.7) ppb, in asth-
matics 0.9 (8.3) ppb and in healthy subjects 0.1 (1.2) ppb.
The mean di¡erence of NOexp values recorded at the
baseline and at 6h in healthy controls did not di¡er from
that of the group of respiratory symptoms (P=0.94) orTABLE 2. Exhalednitric oxide (ppb) and its short-termvariabilit
Baselinemean (ppb) SD 10-minm
Healthy subjects 6.6 2.3 6.7
Respiratory symptoms 14.6* 11.1 15.0
Asthma 34.2** 43.0 32.7
ppb = parts per billion, SD = standard deviation,CoV= coe⁄c
*P= 0.0076,
** Po0.001comparedwiththehealthy subjects.
FIG 1. Individual di¡erences of NOexp values measured at the
baseline and after 10min related to their mean values (mean
NOexp).95%CI = 95% con¢denceinterval.Twopoints areoutside
the ¢gure.asthmatics (P=0.73). That di¡erence was also similar
when comparing asthmatics and the group of respira-
tory symptoms (P=0.72). CoV after 6h compared with
the baseline was 10.8% in healthy subjects, 16.4% in the
group of respiratory symptoms and 19.4% in asthmatics
(Table 2).
The mean (SD) di¡erence of NOexp at 24h compared
with the baseline was 0.7 (9.8) ppb for all study subjects.
In healthy controls, the mean (SD) di¡erence after 24h
compared with baseline was 0.9 (1.3) ppb, in the group
of respiratory symptoms 0.16 (10.9) ppb and in asthmatics
1.4 (14) ppb.The di¡erence of NOexp between the base-
line and 24h healthy subjects did not di¡er from the
group of respiratory symptoms (P=0.82) or in asth-
matics (P=0.88). Furthermore, the di¡erence of NOexp
between thebaseline and 24hwas statistically not signif-
icant between the asthmatics and patients in the group
of respiratory symptoms (P=0.78). CoV of NOexp be-
tween the values at the baseline and at 24hwas11. 7% in
healthy subjects, 22.2% in the group of respiratory
symptoms and 26.4% in asthmatics (Table 2).
DISCUSSION
This study shows that determination of exhaled NO is
well reproducible in youngmen with asthma or asthma-
like symptoms as well as in young healthy adults. The
short-termvariability of the determinationswithin an in-
terval of 24h seemed to be about two times as high as
within an interval of10min, in terms of CoV, both in asth-
matics and in healthy subjects. Since the mean values of
NOexpwithin an interval of 6h showed almostno change
in asthmatics and in the group of asthma-like respiratory
symptoms, the results convict of no evidence for circa-
dian variation.The situation seemed the same in healthy
subjects.
The method for determination of NOexp was well
documented.We used NO-free gas to avoid the e¡ect
of contamination of NO with laboratory air (22). It is
well known that expiratory air£ow has an in£uence on
NOexp values (11). In our study, expiratory £ow was stan-
dardized to be between 0.09 and 0.12 l/s. While theyin di¡erentgroups during study
ean CoV (%) 6-hmean CoV (%) 24-hmean CoV (%)
5.1 6.5 10.8 5.8 11.7
7.1 14.7 16.4 14.5 22.2
13.5 33.3 19.4 32.8 26.4
ientof variation.
SHORT VARIABILITYOFEXHALEDNO 899European Respiratory Society (ERS) guidelines have re-
commended the range 0.16^0.25 l/s (20), recent ATS
guidelines have recommended a constant £ow of 0.05 l/s
(23).The resistor usedwas large enough to close the soft
palate and was in accordance with the ERS guidelines
(20). Moreover, before measurement, study subjects
rinsed their mouths with sodium bicarbonate to elimi-
nate NO production from saliva (24). NOexp measure-
ments were done before lung function tests to
eliminate the e¡ect of spirometry on NOexp (25).
Patients with asthmatic respiratory symptoms who
did not ful¢ll the diagnostic criteria of asthma hadNOexp
values signi¢cantly higher than in healthy subjects, but
signi¢cantly lower than asthma patients. This ¢nding is
in accordance with the results of the study by RytilA et
al. (26), who showed that patients with respiratory
symptoms suggesting asthma, butwith normal lung func-
tion, had higher number of sputum eosinophils than
healthy subjects, but the degree of eosinophilic in£am-
mationwas less pronounced than in asthmatics.
Short-term reproducibility after the 10-min interval
was good in all groups studied. The intra-class correla-
tion coe⁄cient was 0.95, which was similar to previous
¢ndings of van Rensen et al. (27) (rI40.92) and of Salome
et al. (28) (r1=0.95). de Gouw et al. recorded an rI of 0.81
in mild to moderate asthmatics (29). Gabbay et al. re-
ported a mean di¡erence between the two closest
NOexp values of 0.094ppb (12). In our study, themean dif-
ference of NOexp after 10min compared with baseline
was 0.08ppb in healthy subjects and 0.18ppb in overall,
including patients with asthma. ten Hacken et al. re-
ported a CoVof19% in healthy subjects and10% in asth-
matics within a 10-min interval (15). H˛gman et al.,
measuring NOexp with a £ow of 250ml/s at di¡erent air-
way pressures, found CoV to be 6% (10). In our study, the
variation of NOexp in healthy subjects was 5.1%, which is
lower than in previous reports. Variation of NOexp in
asthmatics was similar to that of previously reported
(15).
CoV values of NOexp within the interval of 6 and 24h
in healthy subjects or in patients with asthma-like symp-
toms or with asthmawere notmutually di¡erent. Silko¡
et al. reported intra-day variation (CoV) of 8.6^11.1% and
inter-day variation of 19.0^23.2% at di¡erent expiratory
£ows in healthy subjects (11).We did not ¢nd any circa-
dian variation of NOexp in any group; however, we did
not measure NOexp during early morning (i.e. 4 a.m.). A
previous report on circadian variation of NOexp has
shown that NOexp was signi¢cantly decreased at 4 a.m.
as comparedwith that at 4p.m. in nocturnal asthma (16).
Long-term variation of NOexp in healthy subjects ac-
cording to our previous study was slightly larger than
short-term variation according to the present study
when using the same method; the CoV within 7 days
was15.8% and within 23 days16.8% (14).The larger varia-
tion in long term than in short term is probably due tobiologic variation in the production of NO in the air-
ways.
This is the ¢rst study where short-term variability of
NOexp has been evaluated by using di¡erent time inter-
vals both in healthy subjects and in patients with con-
¢rmed asthma and in patients with asthmatic
respiratory symptoms. According to the present data,
the variation of NOexp consistently associates with the
time interval of the measurements and with the level of
airways in£ammation suggesting a markedbiologic com-
ponent within the inherent variation. The narrow age
range of the male patients studied may have restricted
the variation.
In conclusion, measurement of NOexp by using a stan-
dardizedmethodwaswell reproducible over a shortper-
iod in short term in healthy subjects, in patients with
asthma-like symptoms and in mild asthma.The variation
of NOexpwas associatedwith the time interval between
the determinations and with the severity of airways in-
£ammation. The level of NOexp was elevated, except in
asthma, also in patients with asthmatic symptoms not
ful¢lling the functional criteria of asthma.
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